

### This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
<b>Infectious disease</b>				
HIV/AIDS	HIV integrase	<p>Macaque studies suggest postcoital dosing of gel-formulated HIV integrase inhibitors could prevent HIV infection. In macaques vaginally challenged twice weekly for 2.5 months with a pathogenic simian-human immunodeficiency virus (SHIV), 5 of 6 receiving vaginal 1% raltegravir gel 3 hours after SHIV exposure remained uninfected, whereas 4 of 4 receiving vaginal placebo gel became infected. Next steps include evaluation of additional integrase inhibitors and modalities for HIV prevention.</p> <p>Merck &amp; Co. Inc. markets the oral HIV integrase inhibitor Isentress raltegravir to treat HIV.</p> <p>Japan Tobacco Inc. and Gilead Sciences Inc. market the integrase inhibitor Vitekta elvitegravir to treat HIV.</p> <p>ViiV Healthcare Ltd. has the integrase inhibitor GSK1265744 in Phase II trials and markets the integrase inhibitor Tivicay dolutegravir to treat HIV.</p> <p><b>SciBX 7(13); doi:10.1038/scibx.2014.376</b>  <b>Published online April 3, 2014</b></p>	<p>Patent application filed; available for licensing from the NIH</p> <p><b>Contact:</b> Whitney Blair, National Institutes of Health, Bethesda, Md.            e-mail: <a href="mailto:blairw2@mail.nih.gov">blairw2@mail.nih.gov</a></p>	<p>Dobard, C. <i>et al. Sci. Transl. Med.</i>; published online March 12, 2014; doi:10.1126/scitranslmed.3007701</p> <p><b>Contact:</b> Walid Heneine, Centers for Disease Control and Prevention, Atlanta, Ga.            e-mail: <a href="mailto:wmh2@cdc.gov">wmh2@cdc.gov</a></p>